VISEN PHARMACEUTICALS
维昇药业

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2561)

SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice (the "**Original Notice**") of the annual general meeting (the "**AGM**") of VISEN Pharmaceuticals (the "**Company**") dated 27 April 2026. This supplemental notice (the "**Supplemental Notice**") should be read together with the Original Notice.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the annual general meeting will be held at Room 1701, 1788 Square, No. 1788 West Nanjing Road, Jing'an District, Shanghai, China on Friday, 26 June 2026 at 10:00 a.m. as scheduled. Terms used in this supplemental notice shall have the same meanings as those defined in the supplemental circular of the Company dated 17 June 2026 (the "**Supplemental Circular**") unless otherwise specified.

In addition to the resolutions set out in the Original Notice, the following additional resolutions will be considered and, if thought fit, to be approved at the AGM:

ORDINARY RESOLUTIONS

2(e). To appoint Mr. Roy Paul Khoury as a non-executive director of the Company;

2(f). To appoint Ms. Sherrie Lynn Glass as a non-executive director of the Company.

2(g). To appoint Mr. Michael J. Chang as a non-executive director of the Company.

For details of the above new resolutions, please refer to the Supplemental Circular of the Company dated 17 June 2026.

This Supplemental Notice should be read in conjunction with the Original Notice. Apart from the amendments set out above, all the information contained in the Original Notice shall remain to have full force and effect.

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, 17 June 2026

Notes:

1. Details of the above resolutions are set out in the supplemental circular dated 17 June 2026 of the Company. Please refer to the AGM Circular for details of other resolutions to be proposed at the AGM.

2. As the proxy form published by the Company on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.visenpharma.com) on 27 April 2026 (the "Original Proxy Form") does not contain the newly added resolutions set out in this supplemental notice, a revised proxy form containing the above newly added resolutions (the "Supplemental Proxy Form") has been prepared and is enclosed in this Supplemental Notice.

3. The Supplemental Proxy Form for use at the AGM is enclosed with the supplemental circular. The Supplemental Proxy Form is to be used for the supplemental resolution set out in the supplemental notice of AGM and will not affect the validity of duly completed Original Proxy Form in respect of the resolutions set out in the AGM Notice included in the AGM Circular. Shareholders who intend to appoint a proxy to attend the AGM and vote on the resolution set out in the supplemental notice of AGM shall complete and return the Supplemental Proxy Form in accordance with the instructions printed thereon. For the avoidance of doubt, if you have completed and returned the Original Proxy Form in accordance with the instructions printed thereon but have not completed and returned the Supplemental Proxy Form, such shareholder's proxy will be entitled to vote on behalf of the shareholder in his/her discretion on the resolution set out in the Supplemental Proxy Form. If you have completed and returned the Supplemental Proxy Form in accordance with the instructions printed thereon but have not completed and returned the Original Proxy Form, such shareholder's proxy will be entitled to vote on behalf of the shareholder in his/her discretion on the resolutions set out in the Original Proxy Form. Completion and return of the Original Proxy Form and/or the Supplemental Proxy Form will not preclude you from attending and voting at the AGM, or any adjournment thereof should you so wish.

   Shareholders who intend to appoint a proxy to attend the AGM and to vote on the resolutions set out in the Original AGM Notice and/or the Supplemental AGM Notice are requested to complete and return the Original Proxy Form and/or Supplemental Proxy Form in accordance with the instructions printed thereon not less than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof (as the case may be). Completion and return of the Original Proxy Form and/or Supplemental Proxy Form will not prevent you from attending and voting in person at the AGM or any adjournment thereof if you so wish.

4. In order to be valid, the supplemental form of proxy must be deposited together with a power of attorney or other authority, if any, under which it is signed or a notarially certified copy of that power or authority, at the offices of the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time for holding the meeting or adjourned meeting (as the case may be).

5. Please pay attention that completion and delivery of the Original Proxy Form and/or the Supplemental Proxy Form will not preclude you from attending and voting at the AGM if you so wish. In such event, the instrument for appointing a proxy shall be deemed to be revoked.

6. The above resolution will be put to vote at the AGM by way of poll.

As at the date of this notice, the Board comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong and Mr. ZHANG Qing as independent non-executive directors.

This supplemental circular (in both English and Chinese versions) has been posted on the Company's website at www.visenpharma.com.

Shareholders may request for printed copy of the circular free of charge or change their choice of means of receipt and language of the Company's corporate communications by sending reasonable notice in writing to the Company's branch registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong or by sending an email to visenpharma.com@computershare.com.hk.

Shareholders who have chosen to receive the Company's corporate communications in either English or Chinese version will receive both English and Chinese versions of this circular since both languages are bound together into one booklet.